U.S. Hemoglobinopathies Market (2024 - 2030) Size, Share & Trends Analysis Report By Type (Thalassemia, Sickle Cell Disease), By Diagnosis (Thalassemia, Sickle Cell Disease), By Therapy, By Region, And Segment Forecasts

Table of Contents

Chapter 1. Methodology and Scope
                   1.1. Market Segmentation & Scope
                   1.2. Segment Definitions
                       1.2.1. Type
                       1.2.2. Diagnosis
                       1.2.3. Therapy
                       1.2.4. Estimates and forecasts timeline
                   1.3. Research Methodology
                   1.4. Information Procurement
                       1.4.1. Purchased database
                       1.4.2. GVR’s internal database
                       1.4.3. Secondary sources
                       1.4.4. Primary research
                   1.5. Information or Data Analysis
                       1.5.1. Data analysis models
                   1.6. Market Formulation & Validation
                   1.7. Model Details
                       1.7.1. Commodity flow analysis (Model 1)
                       1.7.2. Volume price analysis (Model 2)
                   1.8. List of Secondary Sources
                   1.9. List of Primary Sources
                   1.10. Objectives
Chapter 2. Executive Summary
                   2.1. Market Outlook
                   2.2. Segment Outlook
                       2.2.1. Type outlook
                       2.2.2. Diagnosis outlook
                       2.2.3. Therapy outlook
                   2.3. Competitive Insights
Chapter 3. U.S. Hemoglobinopathies Market Variables, Trends & Scope
                   3.1. Market Lineage Outlook
                       3.1.1. Parent market outlook
                       3.1.2. Related/ancillary market outlook
                   3.2. Market Dynamics
                       3.2.1. Market driver analysis
                       3.2.2. Market restraint analysis
                   3.3. U.S. Hemoglobinopathies Market Analysis Tools
                       3.3.1. Industry Analysis - Porter’s Five Forces
                           3.3.1.1. Supplier power
                           3.3.1.2. Buyer power
                           3.3.1.3. Substitution threat
                           3.3.1.4. Threat of new entrant
                           3.3.1.5. Competitive rivalry
                       3.3.2. PESTEL Analysis
                           3.3.2.1. Political landscape
                           3.3.2.2. Technological landscape
                           3.3.2.3. Economic landscape
Chapter 4. U.S. Hemoglobinopathies Market: Type Estimates & Trend Analysis
                   4.1. Type Market Share, 2023 & 2030
                   4.2. Segment Dashboard
                   4.3. U.S. Hemoglobinopathies Market by Type Outlook
                   4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
                       4.4.1. Thalassemia
                           4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                       4.4.2. Sickle cell disease
                           4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                       4.4.3. Other Hb variants
                           4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 5. U.S. Hemoglobinopathies Market: Diagnosis Estimates & Trend Analysis
                   5.1. Diagnosis Market Share, 2023 & 2030
                   5.2. Segment Dashboard
                   5.3. U.S. Hemoglobinopathies Market by Diagnosis Outlook
                   5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
                       5.4.1. Thalassemia
                           5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                           5.4.1.2. Alpha
                               5.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                               5.4.1.2.2. Blood test
                                   5.4.1.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                               5.4.1.2.3. Genetic test
                                   5.4.1.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                               5.4.1.2.4. Prenatal genetic test
                                   5.4.1.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                               5.4.1.2.5. Pre-implantation genetic test
                                   5.4.1.2.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                               5.4.1.2.6. Electrophoresis
                                   5.4.1.2.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                               5.4.1.2.7. Others
                                   5.4.1.2.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                           5.4.1.3. Beta
                               5.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                               5.4.1.3.2. Blood test
                                   5.4.1.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                               5.4.1.3.3. Genetic test
                                   5.4.1.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                               5.4.1.3.4. Prenatal genetic test
                                   5.4.1.3.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                               5.4.1.3.5. Pre-implantation genetic test
                                   5.4.1.3.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                               5.4.1.3.6. Electrophoresis
                                   5.4.1.3.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                               5.4.1.3.7. Others
                                   5.4.1.3.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                       5.4.2. Sickle cell disease
                           5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                           5.4.2.2. Blood test
                               5.4.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                           5.4.2.3. Genetic test
                               5.4.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                           5.4.2.4. Prenatal genetic test
                               5.4.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                           5.4.2.5. Electrophoresis
                               5.4.2.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                           5.4.2.6. Others
                               5.4.2.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                       5.4.3. Hb variants
                           5.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                           5.4.3.2. Blood test
                               5.4.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                           5.4.3.3. Genetic test
                               5.4.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                           5.4.3.4. Prenatal genetic test
                               5.4.3.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                           5.4.3.5. Electrophoresis
                               5.4.3.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                           5.4.3.6. Others
                           5.4.3.7. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 6. U.S. Hemoglobinopathies Market: Therapy Estimates & Trend Analysis
                   6.1. Therapy Market Share, 2023 & 2030
                   6.2. Segment Dashboard
                   6.3. U.S. Hemoglobinopathies Market by Therapy Outlook
                   6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
                       6.4.1. Thalassemia
                           6.4.1.1. Market estimates and forecasts 2018 to 2030, (USD million)
                           6.4.1.2. Alpha
                               6.4.1.2.1. Market estimates and forecasts 2018 to 2030, (USD million)
                               6.4.1.2.2. Blood transfusion
                                   6.4.1.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                                   6.4.1.2.2.2. Iron chelation therapy
                                   6.4.1.2.2.3. Market estimates and forecasts 2018 to 2030 (USD Million)
                               6.4.1.2.3. Bone marrow transplant
                                   6.4.1.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                               6.4.1.2.4. Others
                                   6.4.1.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                           6.4.1.3. Beta
                               6.4.1.3.1. Market estimates and forecasts 2018 to 2030, (USD million)
                               6.4.1.3.2. Blood transfusion
                                   6.4.1.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                                   6.4.1.3.2.2. Iron chelation therapy
                                   6.4.1.3.2.3. Market estimates and forecasts 2018 to 2030 (USD Million)
                               6.4.1.3.3. Bone marrow transplant
                                   6.4.1.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                               6.4.1.3.4. Others
                                   6.4.1.3.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                       6.4.2. Sickle Cell Disease
                           6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                           6.4.2.2. Blood transfusion
                               6.4.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                           6.4.2.3. Hydroxyurea
                               6.4.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                           6.4.2.4. Bone marrow transplant
                               6.4.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                           6.4.2.5. Others
                               6.4.2.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                       6.4.3. (Hb) Variants
                           6.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                           6.4.3.2. Blood transfusion
                               6.4.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                           6.4.3.3. Hydroxyurea
                               6.4.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                           6.4.3.4. Bone marrow transplant
                               6.4.3.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                           6.4.3.5. Others
                           6.4.3.6. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 7. Competitive Landscape
                   7.1. Recent Developments & Impact Analysis, By Key Market Participants
                   7.2. Company/Competition Categorization
                   7.3. Vendor Landscape
                       7.3.1. List of key distributors and channel partners
                       7.3.2. Key customers
                       7.3.3. Key company heat map analysis, 2023
                   7.4. Company Profiles
                       7.4.1. Sangamo Therapeutics, Inc.
                           7.4.1.1. Company overview
                           7.4.1.2. Financial performance
                           7.4.1.3. Product benchmarking
                           7.4.1.4. Strategic initiatives
                       7.4.2. Global Blood Therapeutics, Inc.
                           7.4.2.1. Company overview
                           7.4.2.2. Financial performance
                           7.4.2.3. Product benchmarking
                           7.4.2.4. Strategic initiatives
                       7.4.3. bluebird bio, Inc.
                           7.4.3.1. Company overview
                           7.4.3.2. Financial performance
                           7.4.3.3. Product benchmarking
                           7.4.3.4. Strategic initiatives
                       7.4.4. Emmaus Life Sciences Inc.
                           7.4.4.1. Company overview
                           7.4.4.2. Financial performance
                           7.4.4.3. Product benchmarking
                           7.4.4.4. Strategic initiatives
                       7.4.5. Pfizer, Inc.
                           7.4.5.1. Company overview
                           7.4.5.2. Financial performance
                           7.4.5.3. Product benchmarking
                           7.4.5.4. Strategic initiatives
                       7.4.6. Novartis AG
                           7.4.6.1. Company overview
                           7.4.6.2. Financial performance
                           7.4.6.3. Product benchmarking
                           7.4.6.4. Strategic initiatives
                       7.4.7. Prolong Pharmaceuticals, LLC
                           7.4.7.1. Company overview
                           7.4.7.2. Financial performance
                           7.4.7.3. Product benchmarking
                           7.4.7.4. Strategic initiatives
                       7.4.8. Bioverativ Inc.
                           7.4.8.1. Company overview
                           7.4.8.2. Financial performance
                           7.4.8.3. Product benchmarking
                           7.4.8.4. Strategic initiatives
                       7.4.9. Celgene Corp.
                           7.4.9.1. Company overview
                           7.4.9.2. Financial performance
                           7.4.9.3. Product benchmarking
                           7.4.9.4. Strategic initiatives

List of Tables

Table 1 List of abbreviations
Table 2 U.S. hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
Table 3 U.S. hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
Table 4 U.S. hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
Table 5 U.S. thalassemia market, by diagnosis, 2018 - 2030 (USD Million)
Table 6 U.S. hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
Table 7 U.S. alpha thalassemia market, by diagnosis, 2018 - 2030 (USD Million)
Table 8 U.S. beta thalassemia market, by diagnosis, 2018 - 2030 (USD Million)
Table 9 U.S. thalassemia market, by therapy, 2018 - 2030 (USD Million)
Table 10 U.S. alpha thalassemia market, by therapy, 2018 - 2030 (USD Million)
Table 11 U.S. beta thalassemia market, by therapy, 2018 - 2030 (USD Million)
Table 12 U.S. sickle cell disease market, by diagnosis, 2018 - 2030 (USD Million)
Table 13 U.S. sickle cell disease market, by therapy, 2018 - 2030 (USD Million)
Table 14 U.S. Hb Variants market, by diagnosis, 2018 - 2030 (USD Million)
Table 15 U.S. hemoglobinopathies market, by region, 2018 - 2030 (USD Million)

List of Figures

Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 U.S. hemoglobinopathies market: market outlook
Fig. 9 U.S. hemoglobinopathies competitive insights
Fig. 10 Parent market outlook
Fig. 11 Related/ancillary market outlook
Fig. 12 Penetration and growth prospect mapping
Fig. 13 Industry value chain analysis
Fig. 14 U.S. hemoglobinopathies market driver impact
Fig. 15 U.S. hemoglobinopathies market restraint impact
Fig. 16 U.S. hemoglobinopathies market strategic initiatives analysis
Fig. 17 U.S. hemoglobinopathies market: Type movement analysis
Fig. 18 U.S. hemoglobinopathies market: Type outlook and key takeaways
Fig. 19 Thalassemia market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 20 Sickle cell diseases market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 21 Other Hb variants estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 22 U.S. hemoglobinopathies Market: Diagnosis movement Analysis
Fig. 23 U.S. hemoglobinopathies market: Diagnosis outlook and key takeaways
Fig. 24 Thalassemia market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 25 Alpha market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 26 Blood test market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 27 Genetic test market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 28 Prenatal genetic test market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 29 Pre-implantation genetic test market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 30 Electrophoresis market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 31 Other market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 32 Beta market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 33 Blood test market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 34 Genetic test market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 35 Prenatal genetic test market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 36 Pre-implantation genetic test market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 37 Electrophoresis market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 38 Other market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 39 Sickle cell disease market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 40 Blood test market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 41 Genetic test market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 42 Prenatal genetic test market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 43 Electrophoresis market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 44 Others market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 45 (Hb) variants market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 46 Blood test market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 47 Genetic test market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 48 Prenatal genetic test market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 49 Electrophoresis market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 50 Others market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 51 U.S. hemoglobinopathies Market: Therapy movement Analysis
Fig. 52 U.S. hemoglobinopathies market: Therapy outlook and key takeaways
Fig. 53 Thalassemia market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 54 Alpha market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 55 Blood transfusion market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 56 Iron chelation therapy market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 57 Bone marrow transplant test market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 58 Others market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 59 Beta market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 60 Blood transfusion market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 61 Iron chelation therapy market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 62 Bone marrow transplant test market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 63 Others market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 64 Sickle cell disease market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 65 Blood transfusion market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 66 Hydroxyurea market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 67 Bone marrow transplant test market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 68 Others market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 69 (Hb) variants market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 70 Blood transfusion market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 71 Hydroxyurea market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 72 Bone marrow transplant test market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 73 Others market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 74 U.S. hemoglobinopathies market: regional movement analysis
Fig. 75 U.S. hemoglobinopathies market: regional outlook and key takeaways
Fig. 76 West market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 77 Midwest market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 78 Northeast market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 79 Southwest market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 80 Southeast market estimates and forecasts, 2018 - 2030 (USD Million)